Purpose: To evaluate the activity and tolerance of docetaxel in combination with mitoxantrone and granulocyte colonystimulating factor (G-CSF) as front-line treatment in patients with metastatic breast cancer (MBC).
Introduction
Systemic chemotherapy combining an anthracycline with cyclophosphamide, and with or without 5-fluouracil (5-FU) (i.e., AC, CAF, etc), has been an established front-line treatment of patients with metastatic breast cancer (MBC) with objective responses up to 60%. However, most patients relapse within the first year and their median survival ranges from 24 to 36 months. Newer combinations using taxanes and anthracyclines gave higher objective response rates which may be durable [1] [2] [3] . However it is still unclear whether these new chemotherapy combinations may confer a survival benefit.
Docetaxel is one of the most active new drugs in MBC, with objective responses occurring in up to 62% of chemotherapy-naive patients [4, 5] ; moreover, docetaxel resulted in an objective response rate of 40%-46% in patients with anthracycline-resistant disease [6, 7] , indicating that this drug lacks complete cross-resistance with anthracyclines. In a direct comparison, docetaxel [8] but not paclitaxel [9] was more active than doxorubicin in patients with MBC who had received previous alkylating agent-containing chemotherapy. Moreover, docetaxel can be efficiently combined with doxorubicin [10] or epirubicin [11] with objective responses ranging from 53%o to 81%). It is noteworthy that the combination of docetaxel with anthracyclines is associated with a relatively lower incidence of cardiotoxicity [10, 11] compared with the paclitaxel and doxorubicin combination [1] .
Mitoxantrone is an anthracenedione structurally related to doxorubicin. Phase II studies in chemotherapynaive patients with MBC have shown objective responses ranging from 13%> to 51%>, with a median duration of response ranging from 2 to 39 months [12, 13] . In addition, in vitro studies have revealed that mitoxantrone has a steeper dose-response curve than doxorubicin [14] . The comparison of mitoxantrone with doxorubicin, used either as single agent or in combination with cyclophosphamide and 5-FU, failed to reveal statistically significant differences in terms of response rate, response duration, time to progression and overall survival in two out of three randomized trials [15] [16] [17] ; however, all studies have demonstrated that the toxicity profile of mitoxantrone-based combinations was significantly better than that of doxorubicin-based chemotherapy. Due to its favorable toxicity profile, single agent mitoxantrone at doses up to 25 mg/m 2 was well tolerated in a phase I-II study (18) and higher doses (70 mg/m 2 ) have been used in preparative regimens with autologous blood stem-cell support [19] .
We have recently reported a phase I study combining docetaxel with mitoxantrone and G-CSF support in previously untreated patients with MBC [20] . The recommended doses for subsequent phase II studies were docetaxel 100 mg/m 2 on day 1 and mitoxantrone 20 mg/m 2 on day 8 with G-CSF support. This administration schedule was chosen because of the difficulty in administering the drugs at an appropriate dosage, either both on day 1 or separately on two consecutive days [20] . The dose-limiting events were febrile neutropenia, grade 4 neutropenia and grade 3 diarrhea; no significant cardiotoxicity was observed. An overall response rate of 78% (CR = 22% and PR = 56%) was obtained [20] . These findings suggested that this intensified regimen was feasible with G-CSF support. The Greek Cooperative Group for Breast Cancer Research conducted this multicenter phase II study in order to further evaluate the tolerance and activity of this docetaxel-mitoxantrone combination.
Patients and methods

Patients
Patients with histologically confirmed and bidimensionally measurable metastatic breast cancer, aged less than 75 years were enrolled onto the study. Adjuvant chemotherapy was allowed, provided that the received cumulative doxorubicin dose was less than 300 mg/m 2 No prior chemotherapy for metastatic disease was permitted. Other inclusion criteria were: a World Health Organization (WHO) performance status (PS) of 0-2; a life expectancy of. at least, three months: adequate hematologic parameters, including an absolute neutrophil count (ANC) of more than 1500/dl. a hemoglobin level > 10 g/dl. a platelet count > 100.000/dl. plus an adequate liver (serum bihrubin <15 mg/dl). renal (serum creatinine < 1.5 mg/dl) and cardiac (left ventricular ejection fraction (LVEF) > 50%) function. Patients with brain metastases were eligible provided that they had been irradiated and they were clinically and radiologically stable. Patients with a second primary tumor, except an in situ cervical carcinoma or a non-melanoma skin cancer, history of heart failure, uncontrolled angina pectoris or coronary insufficiency within the previous six months were excluded from the study. Other exclusion criteria were radiation therapy within four weeks before initiation of treatment, irradiation of more than 25% of the bone-marrow-containing bones, severe infection or malnutrition. The study was approved by the Ethical and Scientific Committees of the participating Centers, and all patients gave written informed consent to participate in the study. All clinical data were centrally collected and analyzed (Unit of Clinical Trials. Department of Medical Oncology. University General Hospital of Heraklion, Crete) Treatment Docetaxel (Taxotere; Rhone-Poulenc Rorer: Collegeville. Pennsylvania, USA) was administered at a dose of 100 mg/m 2 in 250 ml normal saline over a one-hour infusion on day I. All patients received a standard pre-and post-medication regimen with oral dexamethasone as already reported [20] . Mitoxantrone (Novantrone, Lederle-Wyeth, Indianapolis, USA), was given at the dose of 20 mg/m 2 in 50 ml normal saline over a 15-min infusion on day 8. All patients received standard anti-emetic treatment with odansetron (16 mg i.v. before the administration of cytotoxic drugs, and 8 mg p.o. bid for two consecutive days post-chemotherapy). G-CSF (150 mcg/m 2 /day s.c; Granocyte, Rhone-Poulenc Rorer) was administered prophylactically to all patients from day 2 to day 6 and from day 9 to day 15. Treatment was administered on an outpatient basis and was repeated every three weeks if the ANC was > 1500/dl and the non-hematologic toxicities, except of alopecia, had been resolved Patients were scheduled to receive six cycles of chemotherapy.
Based on the toxicity results of the phase I study [20] , the following dose adjustment criteria were adopted: the docetaxel dose was reduced by 25% in subsequent cycles in case of grade 3 or 4 neutropenia occurring between day 2 and day 10 of the cycle; a similar dose reduction of mitoxantrone was performed in patients with grade 3 or 4 neutropenia occurring between day II and day 21. In addition, grade 3-4 thrombocytopenia, febrile neutropenia, or 5= grade 2 mucositis, necessitated a 20% dose reduction of both drugs. A 25% reduction of docetaxel dose was performed in cases of grade 3-4 diarrhea and grade > 3 asthenia or neurotoxicity.
Patients'evaluation
Baseline evaluations included the following: patient history, physical examination, chest X-rays, complete blood count (CBC) with differential and platelet counts, blood chemistry, ECG and echocardiography or MUGA scan with LVEF measurement, computed tomography (CT) scans of the chest, abdomen and pelvis; brain CT scans were performed when clinically indicated. CBCs with differential and platelet counts were performed routinely twice weekly or daily in patients with grade 3-4 neutropenia or thrombocytopenia or febrile neutropenia; blood chemistry and physical examination were performed every three weeks. Toxicities were graded according to the WHO criteria [21] . Cardiac monitoring consisted of pertinent history, physical examination and ECG every three weeks; echocardiography or MUGA scans were performed after the third and/or the sixth chemotherapy cycle. The treatment was discontinued and the patient was taken off protocol in case of either >20% reduction of LVEF from baseline or LVEF values <50%.
The evaluation of response to treatment, using the WHO criteria [21] , was performed before each cycle for lesions assessable by physical examination or chest X-rays; in all patients, response to treatment was evaluated by imaging studies every three chemotherapy courses and patients achieving complete response (CR), partial response (PR) and stable disease (SD) received a maximum of six chemotherapy cycles. Patients experiencing progressive disease (PD) during the treatment were withdrawn from the study. Standard response criteria [21] were used to define CR, PR, SD and PD. Radiological responses were confirmed by an independent panel of two radiologists. CR and PR had to be maintained fora minimum of four weeks.
Statistical consideration
Response to treatment was the primary end-point of the trial. According to the study design, if a CR rate exceeding 10% was achieved in the first 25 patients (i.e., at least 3 patients achieving CR) then an additional 25 patients would be enrolled to further evaluate the activity of this regimen. This was based on the high CR rate (22%) observed in the phase I trial [20] , The duration of response was measured from the first documentation of response to disease progression Overall survival was measured from study entry to death or last follow-up visit. Actuarial probability of survival was estimated using the Kaplan-Meier method [22] . Qualitative factors were compared by contingency table analysis [23] using the Pearson's x 2 -tesl and the confidence intervals for response rates were calculated using the exact binomial distribution (11) 16 (30) 38 (70) 35 (65) 17 (31) 2 (4) 16 (30) 29 (54) 19 (35) 48 (89) 11 (20) 24 (44) 6 (12) 19 (35) 14 (26) 21 (39) 7 (13) 17 (31) 11 ( 
Results
Patient characteristics
Between January 1997 and March 1998, 54 patients with MBC were enrolled onto the study. All patients were evaluable for toxicity and 52 for response to treatment. One patient was not evaluable for response because of major protocol violation (alternate sequences of docetaxel and mitoxantrone every three weeks) whereas another patient stopped treatment early because of a decline in performance status. Both patients were included in the response results and were considered as progressors. The patient characteristics are shown in Table 1 .
Response to treatment and survival
In an intention-to-treat analysis, complete response (CR) was documented in nine (17%) and partial response (PR) in 24 (44%) patients for an overall response rate of 61% (95% CI: 48.1%-74.1%). Stable disease was observed in 12 (22%) patients and PD in 9 (17%). Responses were observed in all sites of tumor localization: loco-regional (8 out of 15 patients; 53%), lymph nodes (18 out of 26 patients; 69%), lung (26 out of 48 patients; 54%) and liver (11 out of 19 patients; 58%). Prior adjuvant chemotherapy, both anthracycline-and non-anthracycline-based, as well as menopausal status had no effect on the efficacy of the regimen. The overall response rate (CR + PR) for patients who relapsed in 12 months and for those who relapsed in > 12 months after the completion of the adjuvant chemotherapy was 50% and 80%, respectively (P = 0.01).
The median duration of response was 12.5 months (range 1-39). Seventeen (31.5%) of the responders experienced responses lasting for more than 12 months (range 12.5-39.0 months); for three patients with CR and four with PR response duration ranged from 27 to 39 months. The median time to tumor progression was 14 months (range 2.5-45). Three patients presented isolated CNS relapse while they continued to be in response elsewhere. After a median follow-up period of 17 months (range 1-47), 35 (65%) patients had died; the causes of death were disease progression (31 patients) and treatment-related toxicity (1 patient). The median overall survival was 16.5 months (range 1-47); the one-, twoand three-year survival was 61%, 44% and 35%, respectively.
Compliance with the treatment
A total of 256 chemotherapy courses were administered during the study; the median number of cycles per patient was 5 (range 1-6). The median interval between cycles was 25 days (range 21-31). Treatment was discontinued after the first cycle of chemotherapy in four (7%) patients because of disease progression (three patients) and deterioration of PS (one patient). Treatment was discontinued after the third or subsequent chemotherapy cycle in 17 patients for the following reasons: grade 4 neutropenia (seven patients), disease progression (six patients), deterioration of PS (three patients) and toxic death (one patient). Eighty-one (32%) chemotherapy cycles were delayed because of either hematologic (68 cycles; 27%) and/or non-hematologic (13 cycles; 5%) toxicity.
Fifty-two (20%) chemotherapy cycles required dose reduction because of grade 3-4 neutropenia (n = 34; 13%), non-hematologic toxicity (n = 8; 3%) and other reasons non-related to the disease or the treatment (n -10; 4%). Overall, docetaxel was reduced in 18 (7%) cycles and mitoxantrone in 42 (17% (6) 2 (4) 15 (28) 29 (54) 1 (2) 0(0) 1(2)"
Death due to sepsis for docetaxel (range 18-33; corresponding to 85% of the protocol predicted dose) and 5.2 mg/m 2 /week for mitoxantrone (range 2.4-6.6; corresponding to 79% of the protocol predicted dose).
Toxicity
Myelosuppression was the main toxicity of the regimen (Table 2) . Two patients (4%) developed grade 3 anemia, requiring red blood cell transfusions and/or administration of recombinant human erythropoietin. One (2%) patient developed grade 4 thrombocytopenia lasting five days without hemorrhagic complications; no transfusions of platelets were administered. Eight (15%) and twentynine (54%) patients developed grade 3 and 4 neutropenia, respectively; the median duration of grade 3 and 4 neutropenia was three days (range 3-6). Sixteen (30%) patients developed febrile neutropenia requiring hospitalization for treatment with i.v. antibiotics. In two patients, a pathogen was isolated from the blood and/or the urine. One patient developed febrile neutropenia and sepsis after the third chemotherapy cycle; the patient refused hospitalization and died four days later.
The non-hematologic toxicity was relatively mild, mostly of grade I or 2. Indeed, only one patient developed grade 4 mucositis (Table 3) . Alopecia was almost universal. Nausea/vomiting was mainly of grade 2 (46% of the patients). Grade 3 diarrhea occurred in two (4%) patients, and grade 3 neurosensory toxicity in one (2%). Grade 2 and 3 asthenia was reported by 21 (39%) and 3 (6%) patients, respectively. Mild hypersensitivity reactions (pruritus and skin eruption) were observed in 13 (24%) patients but no changes in the treatment plan were required. A moderate fluid retention syndrome (peripheral edema) was observed in seven (13%) patients but it was easily manageable after treatment discontinuation and administration of oral diuretics. Mild to moderately severe nail changes occurred in 10 (19%) patients whilst relatively severe lacrimation was observed in 3 (6%). In no patient was the LVEF decreased with the treatment by more than 10% below the baseline; the median LVEF was 59% (range 52%-65%) before the initiation of chemotherapy and 51% (range 48%-63%) after the completion of six chemotherapy cycles. Seven (13%) patients developed non-neutropenic infections; these included flu-like illness after the first cycle (two patients), upper respiratory infection after the second or fourth cycle Toxicity WHO grade (« = 54)
(two patients), respiratory infection due to Pseudomonas aureginosa after the first cycle (one patient), urinary tract infection due to E. coli after the first cycle (one patient) and gastroenteritis after the first cycle (one patient). Six of them required hospitalization for treatment, and all were resolved uneventfully.
Discussion
The combination of docetaxel with mitoxantrone and rhG-CSF support resulted in an overall response rate of 61% with CRs in 17% of patients with MBC, confirming the results of our previous phase I study [20] . Moreover, the objective response rate was 50% and 80% for patients who relapsed in less or more than 12 months after the completion of adjuvant chemotherapy, respectively. Thus, the activity of this regimen compares favorably to other active front-line chemotherapy regimens which combine paclitaxel or docetaxel with anthracyclines in previously untreated patients with MBC [1, 3, 10, 12, 17] . In a phase I study the combination of docetaxel (80 mg/m 2 ) and mitoxantrone (12 mg/m 2 ) both given on day 1 without rhG-CSF support resulted in an overall response rate of 37% [25] . Similarly, the combination of paclitaxel and mitoxantrone given on day 1 resulted in responses ranging from 35% to 55.6% [26, 27] . The high complete response rate (17%) observed in our phase II study is probably due to the intensification of the chemotherapy regimen. This hypothesis is in agreement with the observation that mitoxantrone has an in vitro steeper dose-response curve than other anthracyclines [14] . Moreover, other studies have demonstrated that the administration of intensified doses of anthracyclines may significantly increase the response rate [28] [29] [30] [31] but it is still unclear whether they can increase the survival of patients with MBC [32] . Furthermore, there are no clear data in the literature to support that the efficacy of docetaxel in MBC is dose-related in terms of response rate or survival.
An interesting observation of the docetaxel-mitoxantrone regimen was the prolonged median duration of response which was 12.5 months. Seventeen (31.5%) patients had durable responses lasting for more than twelve months, whilst seven of them remained in remission for twenty-seven to thirty-nine months. Similar findings have been reported by other investigators. Indeed, Misset et al. [10] reported a two-year survival rate of 66%. In addition, Sparano et al. [33] reported that doxorubicin (60 mg/m 2 ) combined with docetaxel (60 mg/m 2 ) every 3 weeks resulted in 57% objective responses with a median TTP of 7.6 months and an overall survival of 27.5 months. To assess better the efficacy of the study combination in terms of duration of response and survival, a randomized phase III trial comparing the docetaxel-mitoxantrone regimen with a combination of standard doses of either an anthracyclinebased (i.e., CAF, AC, etc.) or a taxane-anthracyclinecontaining regimen is required.
The patients' compliance with the treatment was relatively good since the median delivered dose intensity for docetaxel and mitoxantrone was 85% and 79% of the protocol predicted dose, respectively; however, despite the prophylactic administration of G-CSF, 42 (17%) day 8 doses of mitoxantrone and 18 (7%) day 1 doses of docetaxel were delayed, thus explaining the relatively lower delivered dose intensity for mitoxantrone. It was also mainly due to toxicity that the median number of cycles administered was only 5 (range 1-6). The main toxicity of the regimen was grade 3 and 4 neutropenia occurring in 69% of the patients. Sixteen (30%) patients developed febrile neutropenia and one patient, who refused inpatient treatment, died of sepsis. The incidence of febrile neutropenia in the present study was similar to that observed during the docetaxel-mitoxantrone phase I trial (overall incidence: 21%) [20] . On the other hand, the incidence of grade 3 and 4 anemia or thrombocytopenia was extremely low, as previously reported [20] .
The non-hematologic toxicity of the regimen was mild. Grade 3 neurosensory toxicity was observed in 1 (2%) patient, whilst grade 2 and 3 asthenia was a more frequent complaint reported by 24 (54%) patients. The cardiotoxicity of the docetaxel-mitoxantrone regimen was negligible as already shown in the phase I trial [20] . Therefore, we can conclude that severe cardiotoxicity must be very rare with the docetaxel-mitoxantrone combination. This observation is in overt contrast with the high incidence of cardiotoxicity reported with the paclitaxel-doxorubicin combination [1] . In addition, Misset et al. [10] reported a decrease in the LVEF in four (9.5%) patients with breast cancer treated with a docetaxel-doxorubicin regimen, whilst no patient developed congestive heart failure. Our group has also reported a > 10% decrease in LVEF in four (9%) patients treated with docetaxel and epirubicin [11] . The difference in the cardiotoxicity profile between the docetaxel-mitoxantrone regimen and the other regimens combining taxanes with anthracyclines could be attributed to: i) mitoxantrone has a well known favorable cardiotoxicity profile compared to doxorubicin [12, 13] , and ii) mitoxantrone was given seven days after docetaxel and therefore theoretically no pharmacokinetic interaction should exist between the two drugs. It has been shown that the administration of paclitaxel before doxorubicin may modify the pharmacokinetics of their metabolites thus increasing the toxicity [34] .
In conclusion, our study demonstrates that the combination of docetaxel and mitoxantrone is an active, outpatient and intensified regimen for the treatment of patients with metastatic breast cancer. The activity of this regimen in women with poor-risk disease was promising. However, due to the increased incidence of febrile neutropenia as well as the high cost of the treatment, this regimen cannot be recommended for use outside the context of a clinical trial, at least not before the clear demonstration in phase III studies of its superiority in terms of duration of response and patients' survival.
